Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.45 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31528286 | 1.00 | NCF1 (0.62) | NCF1KDM4EALDH1A1HPGDHTT | |
| SCHEMBL13987728 | 0.87 | NCF1 (0.55) | NCF1KDM4EALDH1A1HPGDHTT | |
| SCHEMBL3340879 | 0.87 | PRMT6 (0.57) | KDM4EALDH1A1HRH3SMN1; SMN2 | |
| SCHEMBL29442395 | 0.87 | PRMT6 (0.57) | KDM4EALDH1A1HRH3SMN1; SMN2 | |
| SCHEMBL5673597 | 0.86 | NCF1 (0.60) | NCF1KDM4EALDH1A1HPGDHTT | |
| SCHEMBL31528239 | 0.85 | SMN1; SMN2 (0.58) | KDM4EALDH1A1HTTHRH3SMN1; SMN2 | |
| SCHEMBL7656309 | 0.85 | SMN1; SMN2 (0.58) | KDM4EALDH1A1HTTHRH3SMN1; SMN2 | |
| SCHEMBL6224362 | 0.84 | SIGMAR1 (0.55) | NCF1HRH3ALDH3A1ALDH1A3PRKDC | |
| SCHEMBL11196105 | 0.84 | NCF1 (0.83) | NCF1KDM4EALDH1A1HPGDHTT | |
| SCHEMBL14261454 | 0.83 | NCF1 (0.57) | NCF1KDM4EALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281119-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEIGENE, LTD. (KY) | 2025-04-22 | — | — | US | disclosed |
| EP-3921320-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | disclosed |
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2022-04-21 | — | — | US | disclosed |
| CN-113454086-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2021-09-28 | — | — | CN | disclosed |
| EP-3294715-B1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2020-05-06 | — | — | EP | disclosed |
| US-20180110755-A1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2018-04-26 | — | — | US | disclosed |
| EP-3294715-A1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | Kancera AB (SE) | 2018-03-21 | — | — | EP | disclosed |
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| WO-2016180472-A1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2016-11-17 | — | — | WO | disclosed |
| US-9238656-B2 | Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders | CEPHALON, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| CN-1630656-A | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORP (JP) | 2005-06-22 | — | — | CN | disclosed |
| EP-1506157-A2 | AMINO-FUNCTIONAL CHALCONES | Lica Pharmaceuticals A/S (DK) | 2005-02-16 | — | — | EP | disclosed |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
| WO-2003097575-A2 | AMINO-FUNCTIONAL CHALCONES | LICA PHARMACEUTICALS A/S (DK) | 2003-11-27 | — | — | WO | disclosed |
| EP-0767798-B1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK AS (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20030004148-A1 | Regulation of meiosis | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | US | disclosed |
| EP-0767798-A1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000235-A1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110755-A1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | HDAC6, HDAC1, HDAC11 | NCF1 525/4885KDM4E 1211/4885ALDH1A1 448/4885 |
| US-20030004148-A1 | Regulation of meiosis | ALPG, MNS1, BUB1B | NCF1 1867/4885KDM4E 1175/4885ALDH1A1 2659/4885 |
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR3 | NCF1 836/4885KDM4E 2575/4885ALDH1A1 1611/4885 |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | MAPKAPK2, MAP3K2, MKNK2 | NCF1 1079/4885KDM4E 2767/4885ALDH1A1 4638/4885 |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | NCF1 3371/4885KDM4E 1992/4885ALDH1A1 944/4885 |
| US-12281119-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR1, TLR3 | NCF1 836/4885KDM4E 2575/4885ALDH1A1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.